All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The ALL Hub is pleased to present a visual abstract representing key data from the phase II INCB84344-201 trial (NCT01641107) evaluating ponatinib plus prednisone as a firstline treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who are aged ≥60 years or considered ineligible for intensive chemotherapy and stem cell transplantation.
Pre-emptive versus prophylactic use of TKIs after allo-SCT in patients with Philadelphia chromosome-positive ALL
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion gene product have revolutionized therapy for patients with...
Ponatinib and venetoclax for patients with Philadelphia chromosome-positive ALL: Interim results of a phase I/II study
The third-generation, pan–BCR-ABL tyrosine kinase inhibitor (TKI), ponatinib, is effective for treating patients with Philadelphia...
Subscribe to get the best content related to ALL delivered to your inbox